Source: www.bloomberg.com Author: Robert Langreth A virus spread by oral sex may cause more cases of throat cancer in men than smoking, a finding that spurred calls for a new large-scale test of a drug used against the infection. Researchers examined 271 throat-tumor samples collected over 20 years ending in 2004 and found that the percentage [...]
Continue reading...Wednesday, April 25, 2012
Source: WebMD.com HPV cancer isn’t just a female problem, new CDC figures show. Although HPV causes 18,000 cancers in women each year, it also causes 8,000 cancers in men, the CDC calculates. To get the figures, CDC researchers analyzed data collected from 2004 to 2008 in two large cancer registries. HPV, human papillomavirus, is the [...]
Continue reading...Wednesday, March 21, 2012
Source: HemOnc Today The American Academy of Pediatrics Committee on Infectious Diseases issued an updated policy statement on human papillomavirus vaccination that recommends both boys and girls be immunized. The policy statement notes vaccination reduces the incidence of sexually transmitted infections and reduces cancer risk. “Persistent infection with high-risk HPV types is responsible for most [...]
Continue reading...Sunday, February 26, 2012
Source: www.cmaj.ca/ Author: Laura Eggertson Provinces weighing the merits of implementing the National Advisory Committee on Immunization’s recommendation to offer human papillomavirus (HPV) vaccine to boys and men aged 9–26 are facing a tricky trade-off between benefits and costs. “I think the benefits are there, but the costs are high,” which is a crucial issue [...]
Continue reading...Wednesday, January 4, 2012
Source: The Lancet Oncology, Volume 13, Issue 1, Pages 10-12, January 2012 In a pair of articles in The Lancet Oncology, Lehtinen and colleagues and Wheeler and colleagues present 4-year end of study data from a trial of a prophylactic human papillomavirus (HPV)-16/-18 vaccine (Cervarix, GlaxoSmithKline) in young women aged 15-25 years. From a public-health [...]
Continue reading...Monday, December 5, 2011
Source: www.telegraph.co.uk Author: Max Pemberton Few politicians will ever admit they are wrong, so I salute health ministers who have finally capitulated to medical opinion and last month announced a U-turn on the cervical cancer vaccine that is given to 12- and 13-year-old girls. Until now, Cervarix, which protects against two strains of the human [...]
Continue reading...Thursday, December 1, 2011
Source: TheNationsHealth.org Vaccination rates for human papillomavirus are lagging for teens, and a complicated web of confusion and misinformation may be to blame, according to public health leaders. Several strains of HPV can cause cervical cancer, and two vaccines, Gardasil and Cervarix, have been shown conclusively to defend against those strains. The Food and Drug [...]
Continue reading...Wednesday, November 30, 2011
Source: National Cancer Institute A bellwether moment in the history of cancer prevention came in 2006 when the Food and Drug Administration (FDA) approved the first vaccine to prevent cervical cancer. The vaccine, Gardasil, protects against the two primary cancer-causing, or oncogenic, types of the human papillomavirus (HPV)—HPV-16 and HPV-18. These types are responsible for [...]
Continue reading...Tuesday, November 29, 2011
Source: National Cancer Institute End-of-trial results from a trial testing Cervarix, a vaccine against human papillomavirus (HPV) types 16 and 18, showed that the vaccine continued to provide substantial protection against cervical precancers 4 years after vaccination. Cervarix provided almost complete protection in young women who had no evidence of exposure to HPV at the [...]
Continue reading...Wednesday, November 16, 2011
Source: Therapeutics Daily Author: Staff LONDON, Nov. 9, 2011-An analysis published today in The Lancet Oncology reinforces previous findings showing that GlaxoSmithKline’s Cervarix®, provided protection against advanced precancerous lesions (CIN3+), above that expected from a vaccine that protects against human papillomavirus (HPV) types 16 and 18. CIN3+ is the immediate step before invasive cervical cancer and data showing protection [...]
Continue reading...
Sunday, May 20, 2012
0 Comments